Literature DB >> 15273959

Modelling relative survival using transformation methods.

Dionne L Price1, Amita K Manatunga.   

Abstract

Patient survival is often assessed as a measure of effectiveness of treatment in cancer clinical trials. The relative survival rate is a measure of patient survival corrected for the effect of other causes of death. We incorporate an additive hazards model for the overall force of mortality focusing attention on the form of the underlying disease process. Transformation models for the cause-specific hazard rate describing the disease process are considered. We demonstrate a method for estimating the transformation parameter providing insight into the appropriate choice of model structure. The models include the additive and multiplicative structures as special cases. We write the models in the generalized linear model framework and demonstrate ease of fitting via existing statistical software. The methodology is applied to a Hodgkin's disease data set to assess the effect of clinical trial results on population survival. Our analysis concludes that the multiplicative structure provides a more appropriate description of the data as compared to the additive structure.

Entities:  

Mesh:

Year:  2004        PMID: 15273959     DOI: 10.1002/sim.1832

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  A class of transformation covariate regression models for estimating the excess hazard in relative survival analysis.

Authors:  Binbing Yu
Journal:  Am J Epidemiol       Date:  2013-03-13       Impact factor: 4.897

2.  Metabolic and evolutionary insights into the closely-related species Streptomyces coelicolor and Streptomyces lividans deduced from high-resolution comparative genomic hybridization.

Authors:  Richard A Lewis; Emma Laing; Nicholas Allenby; Giselda Bucca; Volker Brenner; Marcus Harrison; Andrzej M Kierzek; Colin P Smith
Journal:  BMC Genomics       Date:  2010-12-01       Impact factor: 3.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.